| CARVIEW |
Catena’s CysTyr™ Conjugation Platform
Unlocks Next-Generation
Multi-Payload Conjugates™
Catena’s unique platform enables never-before-possible therapeutic structures and revolutionizes antibody-drug conjugates (ADCs)
With an initial focus on solid tumors with high unmet needs, our Multi-Payload Conjugates (MPCs) deliver dual payloads and show preclinical superiority to current standards of care.
Shortcomings of Current ADCs
Limited to a single type of drug/payload
This results in high rates of resistance/relapse, with very few patients showing durable response.
Limited to small molecule payloads
Current conjugation approaches are unable to readily attach payloads beyond a select group of small molecules, limiting therapeutic options.
Premature release of linker-payload from antibody
Unstable attachment to the antibody leads to the majority of linker-payload being released prematurely before reaching the tumor, resulting in a suboptimal clinical profile.
Catena’s Advantages
Unique payloads at multiple sites
Catena’s CysTyr platform enables attachment of multiple kinds of payloads to the same antibody with flexible drug-to-antibody ratio (DAR) and precise conjugation site control.
Payloads of any size and complexity
Catena’s CysTyr platform utilizes our novel C-Y Bond™ between naturally occurring amino acids (cystine-tyrosine) to create MPCs without limitation of payload size and complexity.
Stability that reduces off-target release
Catena’s C-Y Bond is considerably more stable than traditional maleimide bonds, providing lower off-target release and potentially delivering a superior clinical profile.
CatenaBio Presents Poster on Multi-Payload Conjugates at the American Association for Cancer Research (AACR) Annual Meeting
April 8, 2024 | San Diego, CA
CatenaBio Selected to Present on its Next Generation Platform and Multi Payload Conjugates (MPC®) at the Berkeley Bio Startup Showcase @JPM
January 4, 2024 | Berkeley, CA
Alert: Unauthorized individuals have been falsely claiming to represent CatenaBio. Learn more